Pneumonia最新文献

{"title":"Risk of subsequent lower respiratory tract infection (LRTI) after hospitalization for COVID-19 LRTI and non-COVID-19 LRTI: a retrospective cohort study.","authors":"Katia J Bruxvoort, Heidi Fischer, Joseph A Lewnard, Vennis X Hong, Magdalena Pomichowski, Lindsay R Grant, Luis Jódar, Bradford D Gessner, Sara Y Tartof","doi":"10.1186/s41479-023-00117-5","DOIUrl":"10.1186/s41479-023-00117-5","url":null,"abstract":"<p><strong>Background: </strong>Respiratory pathogens, including SARS-CoV-2, can cause pulmonary structural damage and physiologic impairment, which may increase the risk of subsequent lower respiratory tract infections (LRTI). Prior hospitalization for any reason is a risk factor for LRTI, but data on the risk of subsequent new-onset LRTI following hospitalization for COVID-19 LRTI or non-COVID-19 LRTI are needed to inform strategies for immunizations targeting respiratory pathogens.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study at Kaiser Permanente Southern California (KPSC) among adults hospitalized from 3/1/2020 to 5/31/2022, excluding labor and delivery. We categorized individuals into 3 mutually exclusive baseline exposure groups: those hospitalized for COVID-19 LRTI, those hospitalized for non-COVID-19 LRTI, and those hospitalized for all other causes without LRTI or COVID-19 (\"non-LRTI\"). Following hospital discharge, patients were followed up for new-onset LRTI, beginning 30 antibiotic-free days after hospital discharge until 8/31/2022. We used multivariable cause-specific Cox regression with time-varying covariates to estimate hazard ratios (HR) of new-onset LRTI comparing those hospitalized for COVID-19 LRTI or non-COVID-19 LRTI to those hospitalized for non-LRTI, adjusting for demographic and clinical characteristics.</p><p><strong>Results: </strong>The study included 22,417 individuals hospitalized for COVID-19 LRTI, 12,795 individuals hospitalized for non-COVID-19 LRTI, and 176,788 individuals hospitalized for non-LRTI. Individuals hospitalized for non-COVID-19 LRTI were older and had more comorbidities than those hospitalized for COVID-19 LRTI or non-LRTI. Incidence rates per 1,000 person-years (95% CI) of new-onset LRTI were 52.5 (51.4-53.6) among individuals hospitalized for COVID-19 LRTI, 253.5 (243.7-263.6) among those hospitalized for non-COVID-19 LRTI, and 52.5 (51.4-53.6) among those hospitalized for non-LRTI. The adjusted hazard of new-onset LRTI during follow-up was 20% higher among individuals hospitalized for COVID-19 LRTI (HR 1.20 [95% CI: 1.12-1.28]) and 301% higher among individuals hospitalized for non-COVID-19 LRTI (HR 3.01 [95% CI: 2.87-3.15]) compared to those hospitalized for non-LRTI.</p><p><strong>Conclusion: </strong>The risk of new-onset LRTI following hospital discharge was high, particularly among those hospitalized for non-COVID-19 LRTI, but also for COVID-19 LRTI. These data suggest that immunizations targeting respiratory pathogens, including COVID-19, should be considered for adults hospitalized for LRTI prior to hospital discharge.</p>","PeriodicalId":45120,"journal":{"name":"Pneumonia","volume":"15 1","pages":"15"},"PeriodicalIF":6.8,"publicationDate":"2023-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552217/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41137374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thymalfasin therapy accelerates COVID-19 pneumonia rehabilitation through anti-inflammatory mechanisms.","authors":"Zirui Wang, Cong Wang, Xiaohua Fei, Haixing Wu, Peiqin Niu, Changxing Shen","doi":"10.1186/s41479-023-00116-6","DOIUrl":"10.1186/s41479-023-00116-6","url":null,"abstract":"<p><strong>Introduction: </strong>Thymosin drugs are commonly used for the treatment of viral infections due to their immunomodulatory effects. The comprehensive clinical efficacy of Thymalfasin therapy for COVID-19 associated pneumonia is not yet fully researched, another issue, whether the use of thymosin drugs can reduce the rate of COVID-19 progression to severe pneumonia has not been well documented. The aim of the present study was to multi-angle evaluate the clinical efficacy of Thymalfasin therapy for COVID-19 pneumonia by retrospective review of the clinical data of 338 inpatients with common COVID-19 infection who received treatment in our hospital.</p><p><strong>Methods: </strong>The primary index of observation was whether progression to severe pneumonia occurred within a week after admission, and the secondary indexes were the length of hospital stay, time of negative conversion of COVID-19 antigen, the number of peripheral lymphocytes and white blood cells (WBC), and C-reactive protein (CRP) and procalcitonin (PCT) levels,and the control of pneumonia related symptoms, for example, fever, listlessness, inflammatory exudate area shown on lung CT (%).</p><p><strong>Results: </strong>The length of hospital stay of patients in Thymalfasin group was significantly shorter than that of patients in the control group (p < 0.01). The proportion of relief of pneumonia related symptoms (fever, fatigue) in the Thymalfasin therapy group was significantly higher than that in the control group, and the inflammatory exudate area shown on CT was significantly lower than that in the control group (p < 0.05). Multivariate logistic regression analysis showed that the use of Thymalfasin was an independent protective factor affecting the progression to severe pneumonia. Multifactorial Cox model analysis indicated that negative conversion of COVID-19 antigen was significantly faster in patients using Thymalfasin and younger patients.</p><p><strong>Conclusion: </strong>Thymalfasin therapy has shown excellent clinical efficacy in the treatment of COVID-19 pneumonia, it can reduce inflammatory reactions, promote the relief of COVID-19 pneumonia related symptoms such as fever and fatigue, facilitate effusion absorption, and accelerate COVID-19 pneumonia recovery. Thymalfasin can prevent progression of common COVID-19 infection to severe pneumonia via multiple immunity-enhancing and anti-inflammatory protective mechanisms.</p>","PeriodicalId":45120,"journal":{"name":"Pneumonia","volume":"15 1","pages":"14"},"PeriodicalIF":6.8,"publicationDate":"2023-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518946/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41133187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antibiotic prescription rationality and associated in-patient treatment outcomes in children under-five with severe pneumonia at Bwizibwera health center IV, Mbarara District, South-Western Uganda","authors":"Christine Joy Abeja, Valence Niozima, John Paul Byagamy, C. Obua","doi":"10.1186/s41479-022-00095-0","DOIUrl":"https://doi.org/10.1186/s41479-022-00095-0","url":null,"abstract":"","PeriodicalId":45120,"journal":{"name":"Pneumonia","volume":"14 1","pages":""},"PeriodicalIF":6.8,"publicationDate":"2021-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43536961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of certain underlying comorbidities on the risk of developing hospitalised pneumonia in England","authors":"J. Campling, D. Jones, J. Chalmers, Q. Jiang, A. Vyse, H. Madhava, G. Ellsbury, M. Slack","doi":"10.1186/s41479-019-0063-z","DOIUrl":"https://doi.org/10.1186/s41479-019-0063-z","url":null,"abstract":"","PeriodicalId":45120,"journal":{"name":"Pneumonia","volume":"11 1","pages":""},"PeriodicalIF":6.8,"publicationDate":"2019-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s41479-019-0063-z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47746253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meningococcal pneumonia: a review","authors":"C. Feldman, R. Anderson","doi":"10.1186/s41479-019-0062-0","DOIUrl":"https://doi.org/10.1186/s41479-019-0062-0","url":null,"abstract":"","PeriodicalId":45120,"journal":{"name":"Pneumonia","volume":" ","pages":""},"PeriodicalIF":6.8,"publicationDate":"2019-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s41479-019-0062-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49444171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to: Standardisation and evaluation of a quantitative multiplex real-time PCR assay for the rapid identification of Streptococcus pneumonia","authors":"Feroze A. Ganaie, V. Govindan, K. R. Ravi Kumar","doi":"10.1186/s41479-017-0034-1","DOIUrl":"https://doi.org/10.1186/s41479-017-0034-1","url":null,"abstract":"","PeriodicalId":45120,"journal":{"name":"Pneumonia","volume":"9 1","pages":""},"PeriodicalIF":6.8,"publicationDate":"2017-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s41479-017-0034-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65785941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccination for the control of childhood bacterial pneumonia - <i>Haemophilus influenzae</i> type b and pneumococcal vaccines.","authors":"Diana C Otczyk, Allan W Cripps","doi":"10.15172/pneu.2013.2/229","DOIUrl":"10.15172/pneu.2013.2/229","url":null,"abstract":"<p><p>Pneumonia in childhood is endemic in large parts of the world and in particular, in developing countries, as well as in many indigenous communities within developed nations. <i>Haemophilus influenzae</i> type b and <i>Streptococcus pneumoniae</i> conjugate vaccines are currently available against the leading bacterial causes of pneumonia. The use of the vaccines in both industrialised and developing countries have shown a dramatic reduction in the burden of pneumonia and invasive disease in children. However, the greatest threat facing pneumococcal conjugate vaccine effectiveness is serotype replacement. The current vaccines provide serotype-specific, antibody-mediated protection against only a few of the 90+ capsule serotypes. Therefore, there has been a focus in recent years to rapidly advance technologies that will result in broader disease coverage and more affordable vaccines that can be used in developing countries. The next generation of pneumococcal vaccines have advanced to clinical trials.</p>","PeriodicalId":45120,"journal":{"name":"Pneumonia","volume":"2 ","pages":"2-15"},"PeriodicalIF":8.5,"publicationDate":"2016-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6707409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41215572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anatomical site-specific contributions of pneumococcal virulence determinants","authors":"A. Shenoy, C. Orihuela","doi":"10.1186/s41479-016-0007-9","DOIUrl":"https://doi.org/10.1186/s41479-016-0007-9","url":null,"abstract":"","PeriodicalId":45120,"journal":{"name":"Pneumonia","volume":"8 1","pages":""},"PeriodicalIF":6.8,"publicationDate":"2016-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s41479-016-0007-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65785901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The respiratory microbiota during health and disease: a paediatric perspective","authors":"I. Koppen, A. A. Bosch, E. Sanders, M. V. van Houten, D. Bogaert","doi":"10.15172/pneu.2015.6/656","DOIUrl":"https://doi.org/10.15172/pneu.2015.6/656","url":null,"abstract":"Recent studies investigating the relationship between the microbiota and disease are demonstrating novel concepts that could significantly alter the way we treat disease and promote health in the future. It is suggested that the microbiota acquired during childhood may shape the microbial community and affect immunological responses for later life, and could therefore be important in the susceptibility towards disease. Several diseases, including asthma, pneumonia, and otitis media, are associated with changes in composition and diversity of the respiratory microbiota. This review summarises current literature, focusing on the composition and development of the respiratory microbiota in children and its relationship with respiratory diseases.","PeriodicalId":45120,"journal":{"name":"Pneumonia","volume":"6 1","pages":"90 - 100"},"PeriodicalIF":6.8,"publicationDate":"2015-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.15172/pneu.2015.6/656","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67245413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Salmonella empyema: a case report","authors":"S. Pathmanathan, Suminda Welagedara, Petra Dorrington, Siddhartha Sharma","doi":"10.1007/BF03371465","DOIUrl":"https://doi.org/10.1007/BF03371465","url":null,"abstract":"","PeriodicalId":45120,"journal":{"name":"Pneumonia","volume":"22 1","pages":"120 - 124"},"PeriodicalIF":6.8,"publicationDate":"2015-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF03371465","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"51683039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}